TY - JOUR T1 - Disseminated nontuberculous pulmonary mycobacteriosis in patients at late stages of HIV infection JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2019.PA4633 VL - 54 IS - suppl 63 SP - PA4633 AU - Vladimir Romanov AU - Vladimir Mishin AU - Anastasya Mishina AU - Al;exey Sobkin Y1 - 2019/09/28 UR - http://erj.ersjournals.com/content/54/suppl_63/PA4633.abstract N2 - Aims and Objectives: To study the clinical manifestations and course of disseminated nontuberculous pulmonary mycobacteriosis (DNTPM) in patients with advanced HIV infection and immunosuppression.Methods: 19 patients, aged 20-60, with DNTPM with HIV infection at 4B stage in progression phase and without antiretroviral therapy were under observation. M. avium was isolated from 11 cases, M. intracellular from 3 cases, M. kаnzasii from 3 cases, M. fortuitum from1 case and M. xenopsi from 1 case. In 16 cases DNTPM was combined with secondary diseases and in 18 with drug addiction and viral hepatitis B or C.Results: In 19 cases with DNTPM, CD4 + CLYM averaged 59 c/μl (ranged from 9 to 92). The patients had intestinal disorders (diarrhea), weight loss, peripheral and intrathoracic polylimfoadenopathy, neuropathy and encephalopathy. The clinical picture was characterized by a moderately expressed intoxication syndrome and bronchopulmonary disease manifestations and secondary diseases symptoms in 14 cases (77.8%) (mucocutaneous candidiasis in 14 cases, cytomegalo and herpes virus infection in 11, pneumocystic pneumonia in 8, toxoplasmosis in 2, and lymphoma in 1). A CT scan of the respiratory system secondary to a deformed pulmonary pattern revealed dissemination syndrome, mainly represented by medium and large size foci (3-10 mm) and of medium intensity. They were localized mainly in the middle and lower parts of the lungs and were asymmetric.Conclusion: DNTPM in patients with advanced HIV infection is characterized by a severe immunosuppression with CD4+ CLYM less than 60 c/μl, moderately expressed clinical picture and other secondary diseases (77.8%).FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4633.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -